Epacadostat with pre-op radiation for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding epacadostat (a cancer drug) to standard pre-operative chemoradiation can improve outcomes for people with locally advanced rectal cancer. It’s designed to see if the added treatment is safe and potentially more effective before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (at least 18) with a new, confirmed diagnosis of locally advanced rectal cancer.
- Your cancer treatment plan includes short-course pre-op radiation (total neoadjuvant short course radiation), as your doctor intends.
- You have no prior rectal-cancer treatment (no previous anti-cancer therapy for rectal cancer).
- Your blood counts and key organs (liver, kidneys) are healthy enough for study treatment (specific lab cutoffs apply).
- You must be able to have study procedures, like tumor biopsies, if doctors find them safe and feasible at your site.
- If you could become pregnant or father a child, you must use effective birth control during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new immunotherapy drug (cadonilimab) to standard chemoradiation before surgery helps patients with locally advanced rectal cancer. It aims to improve treatment outcomes by using a shorter course of radiation followed by a combination of the immunotherapy and chemotherapy.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests adding an immunotherapy drug (QL1706) to standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to see if this combination can shrink tumors more effectively.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.